AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30

$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca symbicort (budesonide/formoterol) — Worldwide product sales ($M) ($M)

Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables

Quarterly Annual

Latest, Q2 2026

671

Period ended Jun 30, 2026

Change on a year earlier

-6.2%

715 in Q2 2025

History

42 quarters

Since Q1 2016

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Symbicort (budesonide/formoterol) — Worldwide product sales ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	671	-6.2%	Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026	Mar 31, 2026	747	+3.3%	Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025	Dec 31, 2025	704	+2.9%	Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025	Sep 30, 2025	742	+5.2%	Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025	Jun 30, 2025	715	-1.0%	Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025	Mar 31, 2025	723	-6.0%	Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024	Dec 31, 2024	684	+31.5%	Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024	Sep 30, 2024	705	+27.0%	Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024	Jun 30, 2024	722	+20.3%	Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024	Mar 31, 2024	769	+11.8%	Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023	Dec 31, 2023	520	-16.1%	Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023	Sep 30, 2023	555	-11.9%	Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023	Jun 30, 2023	600	-2.3%	Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023	Mar 31, 2023	688	+2.1%	Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022	Dec 31, 2022	620	-9.0%	Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022	Sep 30, 2022	630	-6.8%	Form 6-K FY2022Q3 Earnings Release ↗
Q2 2022	Jun 30, 2022	614	-9.7%	Form 6-K FY2022Q2 Earnings Release ↗
Q1 2022	Mar 31, 2022	674	-2.5%	Form 6-K FY2022Q1 Earnings Release ↗
Q4 2021	Dec 31, 2021	681	+0.1%	Form 6-K FY2021Q4 Earnings Release ↗
Q3 2021	Sep 30, 2021	676	+12.9%	Form 6-K FY2021Q3 Earnings Release ↗
Q2 2021	Jun 30, 2021	680	+4.1%	Form 6-K FY2021Q2 Earnings Release ↗
Q1 2021	Mar 31, 2021	691	-12.5%	Form 6-K FY2021Q1 Earnings Release ↗
Q4 2020	Dec 31, 2020	680	-4.5%	Form 6-K FY2020Q4 Earnings Release ↗
Q3 2020	Sep 30, 2020	599	-2.3%	Form 6-K (filed 2021-07-30) ↗
Q2 2020	Jun 30, 2020	653	+11.6%	Form 6-K/A (filed 2020-07-31) ↗
Q1 2020	Mar 31, 2020	790	+35.0%	Form 6-K/A (filed 2020-07-31) ↗
Q4 2019	Dec 31, 2019	712	+11.9%	Form 6-K/A (filed 2020-07-31) ↗
Q3 2019	Sep 30, 2019	613	-1.0%	Form 6-K/A (filed 2020-07-31) ↗
Q2 2019	Jun 30, 2019	585	-12.9%	Form 6-K (filed 2019-07-25) ↗
Q1 2019	Mar 31, 2019	585	-7.7%	Form 6-K (filed 2019-07-25) ↗
Q4 2018	Dec 31, 2018	636	-15.4%	Form 6-K (filed 2019-07-25) ↗
Q3 2018	Sep 30, 2018	619	-7.3%	Form 6-K (filed 2019-07-25) ↗
Q2 2018	Jun 30, 2018	672	-4.8%	Form 6-K (filed 2018-07-26) ↗
Q1 2018	Mar 31, 2018	634	-6.4%	Form 6-K (filed 2018-07-26) ↗
Q4 2017	Dec 31, 2017	752	+1.6%	Form 6-K (filed 2018-07-26) ↗
Q3 2017	Sep 30, 2017	668	-4.2%	Form 6-K (filed 2018-07-26) ↗
Q2 2017	Jun 30, 2017	706	-12.1%	Form 6-K (filed 2018-07-26) ↗
Q1 2017	Mar 31, 2017	677	-9.6%	Form 6-K (filed 2018-07-26) ↗
Q4 2016	Dec 31, 2016	740	–	Form 6-K (filed 2018-07-26) ↗
Q3 2016	Sep 30, 2016	697	–	Form 6-K (filed 2018-07-26) ↗
Q2 2016	Jun 30, 2016	803	–	Form 6-K (filed 2018-07-26) ↗
Q1 2016	Mar 31, 2016	749	–	Form 6-K (filed 2018-07-26) ↗

Breakdown

What makes up symbicort (budesonide/formoterol) — worldwide product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Symbicort (budesonide/formoterol) — Worldwide product sales ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_symbicort_world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.